Samsara BioCapital, L.P.

10% owner

Samsara BioCapital, L.P. (10% owner) filed 1 Form 4 report as a reporting entity in the past 24 months (1 purchase, 0 sales), most often in Mineralys Therapeutics, Inc. (MLYS). Across 1 priced purchase filing, the average 21-session return was -6.4% from execution and -2.5% from disclosure (delay-adjusted; derived). The largest single filing was $8.1M of MLYS (600,000 sh × $13.50, as filed), executed Mar 13 2025. Data as of Nov 8 2026.

Add to watchlist

Return, ttmiAverage return per filing, trailing twelve months

-6.4%

avg across 1 priced filings

Delay-adjustediThe same average, entered at disclosure dates

-2.5%

same 1 filings, from disclosure

Filings, ttm

1 buys · 0 sells

Median delay

execution → disclosure

Volume, ttmiDollar value disclosed in the trailing twelve months

$8.1M

shares × price, as filed

Last traded

Mar 13 2025

Filed Mar 17 2025

Median ADV $38.0M across their filed names

Open performance→

Volume by month

Buys $8.1M Sells $0

Shares × price, as filed · by filing month · past 24 months

Sectors filed on

Healthcare 1 filing

Sector per market data · by filing · past 24 months

Most traded names

MLYS Mineralys Therapeutics, Inc. MLYS · 1 buy · 0 sells 1 filing

Recent filings

MLYSPURCHASE Mineralys Therapeutics, Inc. View filing → $8.1M
600,000 sh × $13.50
Exec Mar 13 2025
Filed Mar 17 2025 · 5:30 PM ET